YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Vor Biopharma More than 94% of participants achieved a ≥5-point MG-ADL improvement at Week 48 42% of telitacicept-treated participants achieved minimal symptom expression (MSE) at any time over 48 weeks, increasing from 23.7% over the firs…
Vor Biopharma First regulatory approval for Sjögren's disease (SjD) First and only approved therapy for SjD in China Approval based on positive Phase 3 results generated by collaborator RemeGen demonstrating statistically significant and c…
Vor Biopharma First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) Approval based on positive interim Phase 3 TELIGAN results generated by collaborator RemeGen and recently published in The New England Journal of…
Junshi Biosciences SHANGHAI, May 21, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development…
Vor Biopharma Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks with eGFR remaining stable through treatment Results further support the potential for telitacicept to become a best-in-class…
DelveInsight Business Research LLP The generalized myasthenia gravis treatment pipeline features several promising late-stage candidates, including IMVT-1402 (Immunovant/Roivant Sciences), Descartes-08 (Cartesian Therapeutics), Remibrutini…
In the current landscape, Asian markets are navigating through challenges posed by energy price volatility and geopolitical tensions, which have influenced investor sentiment and economic forecasts. Amid these conditions, companies with st…
Vertex stock popped late Monday on promising test results for a drug that could treat a chronic autoimmune disease that destroys the kidneys. Continue Reading
As global markets navigate a period of volatility, with technology stocks experiencing setbacks and value-oriented sectors gaining traction, investors are increasingly turning their attention to the Asian markets for potential opportunitie…
As global markets navigate a complex landscape, Asian indices have shown mixed performances with Japan's stock markets experiencing declines and China's manufacturing sector displaying modest improvements. In this environment, identifying…
As we enter 2026, the Asian markets are navigating a complex landscape marked by mixed performances across major indices, with China showing signs of manufacturing recovery and South Korea experiencing robust export growth. In this environ…
As global markets grapple with concerns over AI valuations and economic uncertainties, Asian markets have mirrored this cautious sentiment, particularly in China where investor worries about frothy valuations in AI-focused stocks have damp…
As Asian markets navigate a landscape marked by economic fluctuations and investor sentiment shifts, the focus on insider confidence in growth companies becomes increasingly relevant. In this article, we explore three Asian growth companie…
Vor Biopharma Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with a favorable safety profile Telitacicept demonstrated a 55% reduction in 24-hour…
As global markets experience fluctuations driven by geopolitical tensions and economic data releases, Asian stock markets have shown resilience, with key indices in Japan and China posting notable gains. In this environment, identifying st…
Vor Biopharma Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms 100% of patients on telitacicept for 48 weeks achieved ≥2-point Myasthenia Gravis Activities of Daily Living (MG-A…
Vor Biopharma CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a live webcast to present…
As global markets navigate a landscape of easing monetary policies and trade tensions, Asia's economic environment reflects a mix of challenges and opportunities. In this context, growth companies with high insider ownership can be particu…
BERLIN, Oct. 20, 2025 /PRNewswire/ -- At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing local…
Vor Biopharma CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from Stage A of a Phase 3…
RemeGen (SEHK:9995) shares have moved in recent trading, catching the eye of investors interested in biotechnology. With the stock recently closing at HK$95.6, some are evaluating what is driving sentiment around the company’s performance…
Vor Biopharma Trial met primary endpoint achieving statistically significant improvement in disease activity, with 67.1% of patients responding with telitacicept versus 32.7% with placebo Dual inhibition of BAFF and APRIL validated as a tr…
Vor Biopharma Telitacicept met primary and all secondary endpoints, demonstrating clinically meaningful improvements in disease activity versus placebo ~71.8% of patients receiving telitacicept 160mg achieved≥3-point ESSDAI (EULAR Sjögren’…
In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements in ESSDAI [EULAR (European League Against Rheumatism) Sjögren's Syndrome…
Vor Biopharma BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from the Phase 3 study in China ev…
YANTAI, China, Sept. 17, 2025 /PRNewswire/ -- RemeGen (688331.SH/09995.HK) announced that the 48-week open-label extension (OLE) data from China Phase III clinical study of telitacicept (RC18, brand name: 泰爱®, a BLyS/APRIL dual-target fusi…
As global markets navigate a complex landscape shaped by shifting economic indicators and policy changes, Asia's stock markets are capturing attention with their potential for growth amid varying regional dynamics. In this environment, com…
On Wednesday, Vor Bio Inc. (NASDAQ:VOR) announced that its collaborator, RemeGen Co., Ltd., achieved the primary endpoint in Stage A of a Phase 3 clinical study in China evaluating telitacicept in adults with IgA nephropathy (IgAN). IgA ne…
Vor Biopharma Results reinforce telitacicept’s potential across multiple autoimmune diseases Data anticipated to be presented at an upcoming medical conference CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a cl…
As global markets adjust to evolving trade relations and economic indicators, Asian stock markets have shown resilience, with recent developments in China and Japan contributing positively to investor sentiment. In this context, identifyin…
YANTAI, China, Aug. 19, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceutical (Chin…
YANTAI, China, Aug. 18, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceutical (Chin…
As Asian markets experience a period of growth, bolstered by strong corporate earnings and resilient economic indicators, investors are increasingly focusing on companies with robust insider ownership. In this environment, stocks that comb…
[Hand inserts a molecule into DNA.] Natali_Mis/iStock via Getty Images Shares of Vor Bio (NASDAQ:VOR [https://seekingalpha.com/symbol/VOR]) rose after it reported that its partner, RemeGen (OTCPK:REGMF), met the main goal in a late stage t…
Vor Biopharma Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept demonstrated a favorable safety profile Vor evaluating timing of global Phase 3 clinical study in primary Sj…
YANTAI, China, Aug. 13, 2025 /PRNewswire/ -- On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met the primary endpoint in its Phase III c…